Recently discovered BRAF inhibitors may prevent drug-induced skin lesion side effects and lead to greater treatment durability. Mechanism of drug-induced skin lesions is explored in preclinical model. SAN FRANCISCO — Findings from preclinical studies in a skin cancer model showed that next-generation...
Sun, Nov 13 2011
Filed under: Filed under: Press Releases, Research, Treatment, Conference, melanoma, Cancer, Media Materials, AACR, American Association for Cancer Research, meeting, National Cancer Institute, NCI, skin cancer, EGFR, Molecular Targets, AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, Cancer Therapeutics, EORTC, European Organisation for Research and Treatment of Cancer, preclinical studies, Dr. Gideon Bollag, oncogenes, BRAF